Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.

Bioorg Med Chem Lett 2002 Jan;12(2):233-5

Novartis Pharma AG, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.

The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC(50)=1.5nM) are described. The compound inhibited TNFalpha-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(01)00720-xDOI Listing
January 2002

Publication Analysis

Top Keywords

potent selective
8
type inhibitor
8
phosphodiesterase type
8
selective phosphodiesterase
8
ic50=15nm described
4
inhibitor ic50=15nm
4
17-naphthyridine characterization
4
characterization potent
4
model adjuvant-induced
4
described compound
4
active model
4
tnfalpha-release human
4
cells orally
4
orally active
4
inhibited tnfalpha-release
4
compound inhibited
4
peripheral blood
4
mononuclear cells
4
adjuvant-induced arthritis
4
arthritis rats
4

Altmetric Statistics

Similar Publications